Home
- Naturade Significantly Strengthens Balance Sheet; Receives $2.5 Million in Capital from Westgate Equity Partners, L.P.
- Natrol Appoints Vincent Andrich VP Sales for Prolab Division
- Vermont Pure Holdings, Ltd. Announces Record Fiscal Year 2001 Results
- Body Shop Reports 24.8 Mil Euro Sales Revenues
- Supplement Group Targets Consumer Education
- Advanced Nutraceuticals, Inc. Announces 2001 Year End Results And Additional Financing
- ADM Awarded Nutraceuticals Patent Patent Creates Proprietary Position for ADM in Fast-Growing Nutraceutical Market
- Tantivy Sciences Obtains Exclusive License to Unique Nutraceutical Products
- Top GNC Executives Tour Pittsburgh Market to Present New Business Plan and Expansion Possibilities; Meeting will focus on new business strategies and growth
- Nutrition 21 Receives Patent For the Nutritional Treatment of Type 2 Diabetes; Patent Presents New Pharmaceutical Licensing Opportunities
- ConsumerLab.com Finds Most B-vitamin Supplements Contain What They Claim, But Often Exceed Safe Levels - Consumers Cautioned to Be Aware of Side Effects with High Dose Products
- Nutraceutix, Inc., Nutravite Announcement Commercial Availability of CDT™ Glucosamine for Canadian Marketplace
- Harvey Kamil Appointed President of NBTY, Inc. - Scott Rudolph to Continue as Chairman and CEO
- drugstore.com Expects to Reach Profitability Target in 2003
- Human Genome Project Leads to Innovative Healthcare
- NPIcenter’s Career Center targets nutraceutical Industry
- Adding Vitamin C To Certain Drugs May Help Treat Alzheimer's, Other Brain Disorders
- Adding Vitamin C To Certain Drugs May Help Treat Alzheimer's, Other Brain Disorders
- Editorial: An Exercise in Synergy
- NBTY, Inc. Appoints Harvey Kamil President, Scott Rudolph To Continue As Chairman And CEO
- Ross Products to Launch Infant Formula Supplemented With Two New Fatty Acids
- Ross Products to Launch Infant Formula Supplemented With Two New Fatty Acids
- Ross Products to Launch Infant Formula Supplemented With Two New Fatty Acids
- LignisulMSM vs Naproxen for Osteoarthritis Clinical Trial Gets Underway
- Natural Health Trends Corp. Launches Lexxus Taiwan
- New TrimFit® Bars Redefine Energy Bar Category
- New TrimFit® Bars Redefine Energy Bar Category
- Probiata® Offers Safe, Natural and Effective Alternative
- Alive & Well with Michelle Harris
- Be Well and Get Rewarded! Find Personalized Wellness Solutions and Earn Free Vitamins at NatureMade.com
- Consumers Search for Healthy Cleaning Products That Work
- Nordic Naturals: Omega 3 Fatty Acids
- Cyanotech Names Bob Capelli as Director of Sales
- Nutraceutical Clinical Laboratories International, Inc., Secures $2 Million in Funding
- KAVA ADVISORY: Health Canada is advising consumers not to use any products containing kava
- Pharmaceutical Consulting Services, LLC offers a new “cost effective” concept in GMP Compliance
Pharmaceutical Consulting Services, LLC is presenting a program in which for a very small monthly fee, PCS conducts quarterly GMP audits, issues audit reports with non-compliance issues clearly indicated, and works with the company’s staff in finding solutions for the non-compliance issues.
- First assessment of Cognis Tonalin® CLA in EU Novel Food authorisation process completed
Cognis has announced that the Spanish authority for Food Safety and Nutrition (AESAN) has finalized its assessment of Tonalin® in the EU’s Novel Food authorisation process, following the company’s submission of a comprehensive dossier on its leading Tonalin® CLA brand in 2007.
- First assessment of Cognis Tonalin® CLA in EU Novel Food authorisation process completed
Cognis has announced that the Spanish authority for Food Safety and Nutrition (AESAN) has finalized its assessment of Tonalin® in the EU’s Novel Food authorisation process, following the company’s submission of a comprehensive dossier on its leading Tonalin® CLA brand in 2007.
- First assessment of Cognis Tonalin® CLA in EU Novel Food authorisation process completed
Cognis has announced that the Spanish authority for Food Safety and Nutrition (AESAN) has finalized its assessment of Tonalin® in the EU’s Novel Food authorisation process, following the company’s submission of a comprehensive dossier on its leading Tonalin® CLA brand in 2007.
- First assessment of Cognis Tonalin® CLA in EU Novel Food authorisation process completed
Cognis has announced that the Spanish authority for Food Safety and Nutrition (AESAN) has finalized its assessment of Tonalin® in the EU’s Novel Food authorisation process, following the company’s submission of a comprehensive dossier on its leading Tonalin® CLA brand in 2007.
- First assessment of Cognis Tonalin® CLA in EU Novel Food authorisation process completed
Cognis has announced that the Spanish authority for Food Safety and Nutrition (AESAN) has finalized its assessment of Tonalin® in the EU’s Novel Food authorisation process, following the company’s submission of a comprehensive dossier on its leading Tonalin® CLA brand in 2007.
- First assessment of Cognis Tonalin® CLA in EU Novel Food authorisation process completed
Cognis has announced that the Spanish authority for Food Safety and Nutrition (AESAN) has finalized its assessment of Tonalin® in the EU’s Novel Food authorisation process, following the company’s submission of a comprehensive dossier on its leading Tonalin® CLA brand in 2007.
- Sabinsa Corporation Receives GRAS Notification for its Branded Ingredient Cococin(TM)
Sabinsa Corporation has announced that it has received Generally Recognized As Safe (GRAS) status for its branded ingredient Cococin(TM), coconut water solids, after an intensive review of safety and toxicology data by an independent panel of respected scientists assembled by Soni & Associates, Inc.
- Sabinsa Corporation Receives GRAS Notification for its Branded Ingredient Cococin(TM)
Sabinsa Corporation has announced that it has received Generally Recognized As Safe (GRAS) status for its branded ingredient Cococin(TM), coconut water solids, after an intensive review of safety and toxicology data by an independent panel of respected scientists assembled by Soni & Associates, Inc.
- Sabinsa Corporation Receives GRAS Notification for its Branded Ingredient Cococin(TM)
Sabinsa Corporation has announced that it has received Generally Recognized As Safe (GRAS) status for its branded ingredient Cococin(TM), coconut water solids, after an intensive review of safety and toxicology data by an independent panel of respected scientists assembled by Soni & Associates, Inc.
- Sabinsa Corporation Receives GRAS Notification for its Branded Ingredient Cococin(TM)
Sabinsa Corporation has announced that it has received Generally Recognized As Safe (GRAS) status for its branded ingredient Cococin(TM), coconut water solids, after an intensive review of safety and toxicology data by an independent panel of respected scientists assembled by Soni & Associates, Inc.
- Sabinsa Corporation Receives GRAS Notification for its Branded Ingredient Cococin(TM)
Sabinsa Corporation has announced that it has received Generally Recognized As Safe (GRAS) status for its branded ingredient Cococin(TM), coconut water solids, after an intensive review of safety and toxicology data by an independent panel of respected scientists assembled by Soni & Associates, Inc.
- HHS Announces New International Programs to Enhance Drug and Food Safety
U.S. Health and Human Services (HHS) Secretary Mike Leavitt has announced two groundbreaking programs designed to enhance the safety of food and medical products exported to the United States- Joint Inspections with European Union and Australian Regulators and a Third-Party Certification Program.
- HHS Announces New International Programs to Enhance Drug and Food Safety
U.S. Health and Human Services (HHS) Secretary Mike Leavitt has announced two groundbreaking programs designed to enhance the safety of food and medical products exported to the United States- Joint Inspections with European Union and Australian Regulators and a Third-Party Certification Program.
- Larch arabinogalactan from Larix laricina and Larix occidentalis has been approved by the Australian Authorities and is now listed as Therapeutic Goods
The Australian Authorities announced on July 8th that Larch arabinogalactan is now approved as a therapeutically active ingredient for oral use. Three requirements have to be met for approval all of which are fulfilled by Lonza’s active ingredient: the ingredient arabinogalactan (Larix) is derived from Larix larcinia or Larix occidentalis; the concentration of polysaccharides in the ingredient arabinogalactan (Larix) is greater than or equal to 85%; and the maximum recommended daily dose of the ingredient arabinogalactan (Larix) is not to exceed 15 grams.
- Larch arabinogalactan from Larix laricina and Larix occidentalis has been approved by the Australian Authorities and is now listed as Therapeutic Goods
The Australian Authorities announced on July 8th that Larch arabinogalactan is now approved as a therapeutically active ingredient for oral use. Three requirements have to be met for approval all of which are fulfilled by Lonza’s active ingredient: the ingredient arabinogalactan (Larix) is derived from Larix larcinia or Larix occidentalis; the concentration of polysaccharides in the ingredient arabinogalactan (Larix) is greater than or equal to 85%; and the maximum recommended daily dose of the ingredient arabinogalactan (Larix) is not to exceed 15 grams.
- Larch arabinogalactan from Larix laricina and Larix occidentalis has been approved by the Australian Authorities and is now listed as Therapeutic Goods
The Australian Authorities announced on July 8th that Larch arabinogalactan is now approved as a therapeutically active ingredient for oral use. Three requirements have to be met for approval all of which are fulfilled by Lonza’s active ingredient: the ingredient arabinogalactan (Larix) is derived from Larix larcinia or Larix occidentalis; the concentration of polysaccharides in the ingredient arabinogalactan (Larix) is greater than or equal to 85%; and the maximum recommended daily dose of the ingredient arabinogalactan (Larix) is not to exceed 15 grams.
- Larch arabinogalactan from Larix laricina and Larix occidentalis has been approved by the Australian Authorities and is now listed as Therapeutic Goods
The Australian Authorities announced on July 8th that Larch arabinogalactan is now approved as a therapeutically active ingredient for oral use. Three requirements have to be met for approval all of which are fulfilled by Lonza’s active ingredient: the ingredient arabinogalactan (Larix) is derived from Larix larcinia or Larix occidentalis; the concentration of polysaccharides in the ingredient arabinogalactan (Larix) is greater than or equal to 85%; and the maximum recommended daily dose of the ingredient arabinogalactan (Larix) is not to exceed 15 grams.
- IADSA workshop keeps the focus on Latin America
Regulators from Argentina, Chile and Brazil have taken part in workshop in Argentina organised by the International Alliance of Dietary/Food Supplement Associations (IADSA) to address global, regional and national regulatory trends. Held last month in Buenos Aires, the workshop gave the representatives the opportunity to learn about other regulatory systems in the area of dietary supplements.
- IADSA workshop keeps the focus on Latin America
Regulators from Argentina, Chile and Brazil have taken part in workshop in Argentina organised by the International Alliance of Dietary/Food Supplement Associations (IADSA) to address global, regional and national regulatory trends. Held last month in Buenos Aires, the workshop gave the representatives the opportunity to learn about other regulatory systems in the area of dietary supplements.
- Mineral Resources International, Inc. Issues Cease and Desist to Desquera Worldwide Regarding Unlawful Use of Trademarks in Malaysia
Mineral Resources International, Inc. (MRI) announced it has directed the issuance of a cease and desist letter to Desquera Worldwide Sdn Bhd regarding the sale of products labeled with the Trace Minerals Research® and ConcenTrace® brand names.
- Mineral Resources International, Inc. Issues Cease and Desist to Desquera Worldwide Regarding Unlawful Use of Trademarks in Malaysia
Mineral Resources International, Inc. (MRI) announced it has directed the issuance of a cease and desist letter to Desquera Worldwide Sdn Bhd regarding the sale of products labeled with the Trace Minerals Research® and ConcenTrace® brand names.
- Mineral Resources International, Inc. Issues Cease and Desist to Desquera Worldwide Regarding Unlawful Use of Trademarks in Malaysia
Mineral Resources International, Inc. (MRI) announced it has directed the issuance of a cease and desist letter to Desquera Worldwide Sdn Bhd regarding the sale of products labeled with the Trace Minerals Research® and ConcenTrace® brand names.
- Mineral Resources International, Inc. Issues Cease and Desist to Desquera Worldwide Regarding Unlawful Use of Trademarks in Malaysia
Mineral Resources International, Inc. (MRI) announced it has directed the issuance of a cease and desist letter to Desquera Worldwide Sdn Bhd regarding the sale of products labeled with the Trace Minerals Research® and ConcenTrace® brand names.
- Defendants in International Spam Operation Settle FTC Charges; New Canadian Defendants Identified
Defendants in an operation that sold bogus weight loss supplements through illegal spam e-mail have settled Federal Trade Commission charges that their operation violated federal laws. The settlement bars them from making false or unsubstantiated claims about health benefits of any food, drug, or dietary supplements; bars violations of the Controlling the Assault of Non-Solicited Pornography and Marketing Act of 2003, known as the CAN-SPAM Act; and requires them to give up $29,000 in ill-gotten gains.
- Defendants in International Spam Operation Settle FTC Charges; New Canadian Defendants Identified
Defendants in an operation that sold bogus weight loss supplements through illegal spam e-mail have settled Federal Trade Commission charges that their operation violated federal laws. The settlement bars them from making false or unsubstantiated claims about health benefits of any food, drug, or dietary supplements; bars violations of the Controlling the Assault of Non-Solicited Pornography and Marketing Act of 2003, known as the CAN-SPAM Act; and requires them to give up $29,000 in ill-gotten gains.
- Clarinol(TM) CLA: Now GRAS-Approved
Lipid Nutrition has announced that FDA has issued a ‘no objection letter’ to the GRAS petition for Clarinol(TM) CLA, confirming its 'GRAS' status.
- Clarinol(TM) CLA: Now GRAS-Approved
Lipid Nutrition has announced that FDA has issued a ‘no objection letter’ to the GRAS petition for Clarinol(TM) CLA, confirming its 'GRAS' status.
- Clarinol(TM) CLA: Now GRAS-Approved
Lipid Nutrition has announced that FDA has issued a ‘no objection letter’ to the GRAS petition for Clarinol(TM) CLA, confirming its 'GRAS' status.
- Clarinol(TM) CLA: Now GRAS-Approved
Lipid Nutrition has announced that FDA has issued a ‘no objection letter’ to the GRAS petition for Clarinol(TM) CLA, confirming its 'GRAS' status.
- Clarinol(TM) CLA: Now GRAS-Approved
Lipid Nutrition has announced that FDA has issued a ‘no objection letter’ to the GRAS petition for Clarinol(TM) CLA, confirming its 'GRAS' status.
- Federal Authorities Seize Xiadafil VIP Tablets After Company Refuses to Recall Product
At the request of the U.S. Food and Drug Administration, U.S. Marshals seized nearly $74,000 worth of Xiadafil VIP tablets, Lots 6K029 and 6K209-SEI, distributed by SEI Pharmaceuticals, Inc. of Miami, Fla. Although marketed as a dietary supplement to treat erectile dysfunction (ED) and for sexual enhancement, these lots represent an illegally marketed drug containing an undeclared ingredient.
- Federal Authorities Seize Xiadafil VIP Tablets After Company Refuses to Recall Product
At the request of the U.S. Food and Drug Administration, U.S. Marshals seized nearly $74,000 worth of Xiadafil VIP tablets, Lots 6K029 and 6K209-SEI, distributed by SEI Pharmaceuticals, Inc. of Miami, Fla. Although marketed as a dietary supplement to treat erectile dysfunction (ED) and for sexual enhancement, these lots represent an illegally marketed drug containing an undeclared ingredient.
- Federal Authorities Seize Xiadafil VIP Tablets After Company Refuses to Recall Product
At the request of the U.S. Food and Drug Administration, U.S. Marshals seized nearly $74,000 worth of Xiadafil VIP tablets, Lots 6K029 and 6K209-SEI, distributed by SEI Pharmaceuticals, Inc. of Miami, Fla. Although marketed as a dietary supplement to treat erectile dysfunction (ED) and for sexual enhancement, these lots represent an illegally marketed drug containing an undeclared ingredient.
- Federal Authorities Seize Xiadafil VIP Tablets After Company Refuses to Recall Product
At the request of the U.S. Food and Drug Administration, U.S. Marshals seized nearly $74,000 worth of Xiadafil VIP tablets, Lots 6K029 and 6K209-SEI, distributed by SEI Pharmaceuticals, Inc. of Miami, Fla. Although marketed as a dietary supplement to treat erectile dysfunction (ED) and for sexual enhancement, these lots represent an illegally marketed drug containing an undeclared ingredient.
- Novel food catalogue clarity reassuring but concerns remain says EHPM
European trade organisation EHPM has said it is ‘reassured’ by a statement from the European Commission that its recently published novel food catalogue is not legally binding for EU Member States, but has held concerns that listing an ingredient in the catalogue could prejudice its members’ products commercial viability because it may in practice be considered by some national authorities as a novel food ingredient.
- Novel food catalogue clarity reassuring but concerns remain says EHPM
European trade organisation EHPM has said it is ‘reassured’ by a statement from the European Commission that its recently published novel food catalogue is not legally binding for EU Member States, but has held concerns that listing an ingredient in the catalogue could prejudice its members’ products commercial viability because it may in practice be considered by some national authorities as a novel food ingredient.
- Novel food catalogue clarity reassuring but concerns remain says EHPM
European trade organisation EHPM has said it is ‘reassured’ by a statement from the European Commission that its recently published novel food catalogue is not legally binding for EU Member States, but has held concerns that listing an ingredient in the catalogue could prejudice its members’ products commercial viability because it may in practice be considered by some national authorities as a novel food ingredient.
- Novel food catalogue clarity reassuring but concerns remain says EHPM
European trade organisation EHPM has said it is ‘reassured’ by a statement from the European Commission that its recently published novel food catalogue is not legally binding for EU Member States, but has held concerns that listing an ingredient in the catalogue could prejudice its members’ products commercial viability because it may in practice be considered by some national authorities as a novel food ingredient.
- Novel food catalogue clarity reassuring but concerns remain says EHPM
European trade organisation EHPM has said it is ‘reassured’ by a statement from the European Commission that its recently published novel food catalogue is not legally binding for EU Member States, but has held concerns that listing an ingredient in the catalogue could prejudice its members’ products commercial viability because it may in practice be considered by some national authorities as a novel food ingredient.
- Novel food catalogue clarity reassuring but concerns remain says EHPM
European trade organisation EHPM has said it is ‘reassured’ by a statement from the European Commission that its recently published novel food catalogue is not legally binding for EU Member States, but has held concerns that listing an ingredient in the catalogue could prejudice its members’ products commercial viability because it may in practice be considered by some national authorities as a novel food ingredient.
- Capsugel Obtains Australia’s TGA Certification For Its Licaps® Liquid-Fill Capsule Manufacturing Facility
Capsugel has announced that it has received certification from the Therapeutic Goods Administration (TGA) for its Licaps® liquid-fill capsule production facility in Greenwood, S.C. (USA).
- Capsugel Obtains Australia’s TGA Certification For Its Licaps® Liquid-Fill Capsule Manufacturing Facility
Capsugel has announced that it has received certification from the Therapeutic Goods Administration (TGA) for its Licaps® liquid-fill capsule production facility in Greenwood, S.C. (USA).
- Capsugel Obtains Australia’s TGA Certification For Its Licaps® Liquid-Fill Capsule Manufacturing Facility
Capsugel has announced that it has received certification from the Therapeutic Goods Administration (TGA) for its Licaps® liquid-fill capsule production facility in Greenwood, S.C. (USA).
- Capsugel Obtains Australia’s TGA Certification For Its Licaps® Liquid-Fill Capsule Manufacturing Facility
Capsugel has announced that it has received certification from the Therapeutic Goods Administration (TGA) for its Licaps® liquid-fill capsule production facility in Greenwood, S.C. (USA).
- Capsugel Obtains Australia’s TGA Certification For Its Licaps® Liquid-Fill Capsule Manufacturing Facility
Capsugel has announced that it has received certification from the Therapeutic Goods Administration (TGA) for its Licaps® liquid-fill capsule production facility in Greenwood, S.C. (USA).
- EAS Gives Regulatory Crash Course
International food and nutrition policy consultancy EAS will be hosting a workshop entitled ‘Building a Regulatory Strategy for Marketing Food Supplements in Europe: The key steps to a successful product launch,’ October 9th, in Brussels.
- EAS Gives Regulatory Crash Course
International food and nutrition policy consultancy EAS will be hosting a workshop entitled ‘Building a Regulatory Strategy for Marketing Food Supplements in Europe: The key steps to a successful product launch,’ October 9th, in Brussels.
- EAS Gives Regulatory Crash Course
International food and nutrition policy consultancy EAS will be hosting a workshop entitled ‘Building a Regulatory Strategy for Marketing Food Supplements in Europe: The key steps to a successful product launch,’ October 9th, in Brussels.
- EAS Gives Regulatory Crash Course
International food and nutrition policy consultancy EAS will be hosting a workshop entitled ‘Building a Regulatory Strategy for Marketing Food Supplements in Europe: The key steps to a successful product launch,’ October 9th, in Brussels.
- EAS Gives Regulatory Crash Course
International food and nutrition policy consultancy EAS will be hosting a workshop entitled ‘Building a Regulatory Strategy for Marketing Food Supplements in Europe: The key steps to a successful product launch,’ October 9th, in Brussels.
- EAS Gives Regulatory Crash Course
International food and nutrition policy consultancy EAS will be hosting a workshop entitled ‘Building a Regulatory Strategy for Marketing Food Supplements in Europe: The key steps to a successful product launch,’ October 9th, in Brussels.
- Health claims based only on human intervention studies not practical says IADSA
Commenting on the latest draft Codex Alimentarius recommendations for the scientific basis of health claims, IADSA said that while the clinical trial model is one source of scientific data, it is not practical when applied to the reduction of risk of disease in persons generally regarded as ‘healthy’.
- Health claims based only on human intervention studies not practical says IADSA
Commenting on the latest draft Codex Alimentarius recommendations for the scientific basis of health claims, IADSA said that while the clinical trial model is one source of scientific data, it is not practical when applied to the reduction of risk of disease in persons generally regarded as ‘healthy’.
- Health claims based only on human intervention studies not practical says IADSA
Commenting on the latest draft Codex Alimentarius recommendations for the scientific basis of health claims, IADSA said that while the clinical trial model is one source of scientific data, it is not practical when applied to the reduction of risk of disease in persons generally regarded as ‘healthy’.
- Health claims based only on human intervention studies not practical says IADSA
Commenting on the latest draft Codex Alimentarius recommendations for the scientific basis of health claims, IADSA said that while the clinical trial model is one source of scientific data, it is not practical when applied to the reduction of risk of disease in persons generally regarded as ‘healthy’.
- Makers of Airborne Settle FTC Charges of Deceptive Advertising Agreement Brings Total Settlement Funds to $30 Million
Airborne Health, Inc., the Bonita Springs, Florida maker of the popular Airborne Effervescent Health Formula, an effervescent tablet marketed as a cold prevention and treatment remedy, has agreed to pay up to $30 million to settle Federal Trade Commission charges that it did not have adequate evidence to support its advertising claims. If the settlement is approved by the court, it will prohibit the defendants from making false and unsubstantiated cold prevention, germ-fighting, and efficacy claims. The monetary judgment will be satisfied by the defendants’ adding $6.5 million to the funds they have already agreed to pay to settle a related private class-action lawsuit, bringing the total settlement fund to $30 million.
- Makers of Airborne Settle FTC Charges of Deceptive Advertising Agreement Brings Total Settlement Funds to $30 Million
Airborne Health, Inc., the Bonita Springs, Florida maker of the popular Airborne Effervescent Health Formula, an effervescent tablet marketed as a cold prevention and treatment remedy, has agreed to pay up to $30 million to settle Federal Trade Commission charges that it did not have adequate evidence to support its advertising claims. If the settlement is approved by the court, it will prohibit the defendants from making false and unsubstantiated cold prevention, germ-fighting, and efficacy claims. The monetary judgment will be satisfied by the defendants’ adding $6.5 million to the funds they have already agreed to pay to settle a related private class-action lawsuit, bringing the total settlement fund to $30 million.
- Makers of Airborne Settle FTC Charges of Deceptive Advertising Agreement Brings Total Settlement Funds to $30 Million
Airborne Health, Inc., the Bonita Springs, Florida maker of the popular Airborne Effervescent Health Formula, an effervescent tablet marketed as a cold prevention and treatment remedy, has agreed to pay up to $30 million to settle Federal Trade Commission charges that it did not have adequate evidence to support its advertising claims. If the settlement is approved by the court, it will prohibit the defendants from making false and unsubstantiated cold prevention, germ-fighting, and efficacy claims. The monetary judgment will be satisfied by the defendants’ adding $6.5 million to the funds they have already agreed to pay to settle a related private class-action lawsuit, bringing the total settlement fund to $30 million.
- Makers of Airborne Settle FTC Charges of Deceptive Advertising Agreement Brings Total Settlement Funds to $30 Million
Airborne Health, Inc., the Bonita Springs, Florida maker of the popular Airborne Effervescent Health Formula, an effervescent tablet marketed as a cold prevention and treatment remedy, has agreed to pay up to $30 million to settle Federal Trade Commission charges that it did not have adequate evidence to support its advertising claims. If the settlement is approved by the court, it will prohibit the defendants from making false and unsubstantiated cold prevention, germ-fighting, and efficacy claims. The monetary judgment will be satisfied by the defendants’ adding $6.5 million to the funds they have already agreed to pay to settle a related private class-action lawsuit, bringing the total settlement fund to $30 million.
- Makers of Airborne Settle FTC Charges of Deceptive Advertising Agreement Brings Total Settlement Funds to $30 Million
Airborne Health, Inc., the Bonita Springs, Florida maker of the popular Airborne Effervescent Health Formula, an effervescent tablet marketed as a cold prevention and treatment remedy, has agreed to pay up to $30 million to settle Federal Trade Commission charges that it did not have adequate evidence to support its advertising claims. If the settlement is approved by the court, it will prohibit the defendants from making false and unsubstantiated cold prevention, germ-fighting, and efficacy claims. The monetary judgment will be satisfied by the defendants’ adding $6.5 million to the funds they have already agreed to pay to settle a related private class-action lawsuit, bringing the total settlement fund to $30 million.
- Makers of Airborne Settle FTC Charges of Deceptive Advertising Agreement Brings Total Settlement Funds to $30 Million
Airborne Health, Inc., the Bonita Springs, Florida maker of the popular Airborne Effervescent Health Formula, an effervescent tablet marketed as a cold prevention and treatment remedy, has agreed to pay up to $30 million to settle Federal Trade Commission charges that it did not have adequate evidence to support its advertising claims. If the settlement is approved by the court, it will prohibit the defendants from making false and unsubstantiated cold prevention, germ-fighting, and efficacy claims. The monetary judgment will be satisfied by the defendants’ adding $6.5 million to the funds they have already agreed to pay to settle a related private class-action lawsuit, bringing the total settlement fund to $30 million.
- Makers of Airborne Settle FTC Charges of Deceptive Advertising Agreement Brings Total Settlement Funds to $30 Million
Airborne Health, Inc., the Bonita Springs, Florida maker of the popular Airborne Effervescent Health Formula, an effervescent tablet marketed as a cold prevention and treatment remedy, has agreed to pay up to $30 million to settle Federal Trade Commission charges that it did not have adequate evidence to support its advertising claims. If the settlement is approved by the court, it will prohibit the defendants from making false and unsubstantiated cold prevention, germ-fighting, and efficacy claims. The monetary judgment will be satisfied by the defendants’ adding $6.5 million to the funds they have already agreed to pay to settle a related private class-action lawsuit, bringing the total settlement fund to $30 million.
- Makers of Airborne Settle FTC Charges of Deceptive Advertising Agreement Brings Total Settlement Funds to $30 Million
Airborne Health, Inc., the Bonita Springs, Florida maker of the popular Airborne Effervescent Health Formula, an effervescent tablet marketed as a cold prevention and treatment remedy, has agreed to pay up to $30 million to settle Federal Trade Commission charges that it did not have adequate evidence to support its advertising claims. If the settlement is approved by the court, it will prohibit the defendants from making false and unsubstantiated cold prevention, germ-fighting, and efficacy claims. The monetary judgment will be satisfied by the defendants’ adding $6.5 million to the funds they have already agreed to pay to settle a related private class-action lawsuit, bringing the total settlement fund to $30 million.
- Makers of Airborne Settle FTC Charges of Deceptive Advertising Agreement Brings Total Settlement Funds to $30 Million
Airborne Health, Inc., the Bonita Springs, Florida maker of the popular Airborne Effervescent Health Formula, an effervescent tablet marketed as a cold prevention and treatment remedy, has agreed to pay up to $30 million to settle Federal Trade Commission charges that it did not have adequate evidence to support its advertising claims. If the settlement is approved by the court, it will prohibit the defendants from making false and unsubstantiated cold prevention, germ-fighting, and efficacy claims. The monetary judgment will be satisfied by the defendants’ adding $6.5 million to the funds they have already agreed to pay to settle a related private class-action lawsuit, bringing the total settlement fund to $30 million.
- Makers of Airborne Settle FTC Charges of Deceptive Advertising Agreement Brings Total Settlement Funds to $30 Million
Airborne Health, Inc., the Bonita Springs, Florida maker of the popular Airborne Effervescent Health Formula, an effervescent tablet marketed as a cold prevention and treatment remedy, has agreed to pay up to $30 million to settle Federal Trade Commission charges that it did not have adequate evidence to support its advertising claims. If the settlement is approved by the court, it will prohibit the defendants from making false and unsubstantiated cold prevention, germ-fighting, and efficacy claims. The monetary judgment will be satisfied by the defendants’ adding $6.5 million to the funds they have already agreed to pay to settle a related private class-action lawsuit, bringing the total settlement fund to $30 million.
- Makers of Airborne Settle FTC Charges of Deceptive Advertising Agreement Brings Total Settlement Funds to $30 Million
Airborne Health, Inc., the Bonita Springs, Florida maker of the popular Airborne Effervescent Health Formula, an effervescent tablet marketed as a cold prevention and treatment remedy, has agreed to pay up to $30 million to settle Federal Trade Commission charges that it did not have adequate evidence to support its advertising claims. If the settlement is approved by the court, it will prohibit the defendants from making false and unsubstantiated cold prevention, germ-fighting, and efficacy claims. The monetary judgment will be satisfied by the defendants’ adding $6.5 million to the funds they have already agreed to pay to settle a related private class-action lawsuit, bringing the total settlement fund to $30 million.
- FDA Announces a Final Rule in Regards to Soluble Fiber Sources
The Food and Drug Administration (FDA) is adopting as a final rule, without
change, the provisions of the interim final rule (IFR) that amended the
regulation authorizing a health claim on soluble fiber from certain foods and
risk of coronary heart disease (CHD), to add barley betafiber as an additional
eligible source of beta-glucan soluble fiber. FDA is taking this action to
complete the rulemaking initiated with the IFR.
- FDA Announces a Final Rule in Regards to Soluble Fiber Sources
The Food and Drug Administration (FDA) is adopting as a final rule, without
change, the provisions of the interim final rule (IFR) that amended the
regulation authorizing a health claim on soluble fiber from certain foods and
risk of coronary heart disease (CHD), to add barley betafiber as an additional
eligible source of beta-glucan soluble fiber. FDA is taking this action to
complete the rulemaking initiated with the IFR.
- FDA Announces a Final Rule in Regards to Soluble Fiber Sources
The Food and Drug Administration (FDA) is adopting as a final rule, without
change, the provisions of the interim final rule (IFR) that amended the
regulation authorizing a health claim on soluble fiber from certain foods and
risk of coronary heart disease (CHD), to add barley betafiber as an additional
eligible source of beta-glucan soluble fiber. FDA is taking this action to
complete the rulemaking initiated with the IFR.
- Frost & Sullivan Honours GAT Food Essentials GmbH With European Functional Food & Beverage Microencapsulation Technology Innovation Award
The 2009 Frost & Sullivan European Functional Food & Beverage Microencapsulation Technology Innovation Award has been presented to GAT Food Essentials GmbH in recognition of its proprietary wowCAPS(R) technology.
- Frost & Sullivan Honours GAT Food Essentials GmbH With European Functional Food & Beverage Microencapsulation Technology Innovation Award
The 2009 Frost & Sullivan European Functional Food & Beverage Microencapsulation Technology Innovation Award has been presented to GAT Food Essentials GmbH in recognition of its proprietary wowCAPS(R) technology.
- Frost & Sullivan Honours GAT Food Essentials GmbH With European Functional Food & Beverage Microencapsulation Technology Innovation Award
The 2009 Frost & Sullivan European Functional Food & Beverage Microencapsulation Technology Innovation Award has been presented to GAT Food Essentials GmbH in recognition of its proprietary wowCAPS(R) technology.
- BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates
Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010.
- BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates
Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010.
- BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates
Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010.
- BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates
Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010.
- BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates
Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010.
- BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates
Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010.
- BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates
Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010.
- BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates
Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010.
- BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates
Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010.
- Synergy Flavors Invests in Sensory Flavor Profiling Research
Synergy Flavors has commissioned a new research program at North Carolina State University to study the sensory profiles of a range of protein ingredients.
- Synergy Flavors Invests in Sensory Flavor Profiling Research
Synergy Flavors has commissioned a new research program at North Carolina State University to study the sensory profiles of a range of protein ingredients.
- Synergy Flavors Invests in Sensory Flavor Profiling Research
Synergy Flavors has commissioned a new research program at North Carolina State University to study the sensory profiles of a range of protein ingredients.
- Synergy Flavors Invests in Sensory Flavor Profiling Research
Synergy Flavors has commissioned a new research program at North Carolina State University to study the sensory profiles of a range of protein ingredients.
- Synergy Flavors Invests in Sensory Flavor Profiling Research
Synergy Flavors has commissioned a new research program at North Carolina State University to study the sensory profiles of a range of protein ingredients.
- Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors
Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders.
- Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors
Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders.
- Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors
Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders.
- Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors
Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders.
- Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors
Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders.
- Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors
Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders.
- Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors
Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders.
- NPI Daily - Top of The News for Nov. 20, 2009 - FDA Issues 22 Warning Letters to Website Operators
Frost & Sullivan Honours GAT Food Essentials GmbH With European Functional Food & Beverage Microencapsulation Technology Innovation Award; Synergy Flavors Invests in Sensory Flavor Profiling Research; FDA Issues 22 Warning Letters to Website Operators; Nordic Naturals Ultimate Omega™ First Fish Oil to Participate in NFL/NFLPA Sports Nutrition Label Certification Program; BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates; New Organic Berry Whole Food Energy Bar from Amazing Grass Delivers Whole Food Nutrition; Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors
- NPI Daily - Top of The News for Nov. 20, 2009 - FDA Issues 22 Warning Letters to Website Operators
Frost & Sullivan Honours GAT Food Essentials GmbH With European Functional Food & Beverage Microencapsulation Technology Innovation Award; Synergy Flavors Invests in Sensory Flavor Profiling Research; FDA Issues 22 Warning Letters to Website Operators; Nordic Naturals Ultimate Omega™ First Fish Oil to Participate in NFL/NFLPA Sports Nutrition Label Certification Program; BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates; New Organic Berry Whole Food Energy Bar from Amazing Grass Delivers Whole Food Nutrition; Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors
- Heart Health Alert: Niacin May Reverse Hardening of the Arteries
- Heart Health Alert: Niacin May Reverse Hardening of the Arteries
- Heart Health Alert: Niacin May Reverse Hardening of the Arteries
- Heart Health Alert: Niacin May Reverse Hardening of the Arteries
- Spotlight on Savory Side Dishes
- Spotlight on Savory Side Dishes
- Spotlight on Savory Side Dishes
- Another Reason to Choose Healthy Lifestyle Habits
- Another Reason to Choose Healthy Lifestyle Habits
|
July 28, 2008, LaGrange, IL -- Cognis Nutrition and Health, global leader in the manufacture of the most clinically studied brand of CLA (conjugated linoleic acid), today announced that the U.S. Food and Drug Administration (FDA) issued a ‘no questions letter’ to Cognis’ GRAS notification (GRN 00232). Tonalin® (Tōn-a-lin) CLA has achieved FDA GRAS (generally recognized as safe) status and can be safely used in an expanded range of functional foods and beverages. Cognis offers the food industry one of the most extensive lines of CLA, a naturally sourced, non-stimulant ingredient clinically proven to safely reduce body fat and improve body composition.
Cognis is sponsoring a free, live webcast on August 14, 2008 to explain the commercial opportunities and consumer benefits to be derived from this FDA GRAS status for Tonalin® CLA. Trends expert, Dr. Elizabeth Sloan, will highlight the current consumer dynamics driving market demand for body composition products and present valuable new market data that food and beverage makers can’t afford to miss. She will share new consumer market research indicating that sales for functional foods containing ingredients such as Tonalin® CLA are projected to be “off the charts.”
Register now for free, live webcast!
To attend the webcast, register at http://www.iian.ibeam.com/events/mult001/26560/. You may submit questions during the live Q&A and the event will be archived for later viewing.
The new FDA GRAS status expands the use of Tonalin® CLA into the following approved food applications:
• Milk and flavored milk products
• Yogurt products
• Fruit juice products
• Soy milk beverages
• Meal replacement beverages and bars
In addition to the applications above, Cognis’ Tonalin® CLA is also self-affirmed GRAS for:
• Coffee creamers
• Chocolate
Tonalin® CLA has been thoroughly evaluated in several functional food applications, especially in the dairy segment. Potential for the success of Tonalin® in food products was also demonstrated in recent research on its effects in a skimmed milk product. Results of the randomized, double-blind, placebo-controlled trial showed a significant reduction of body fat mass (BFM) in overweight subjects, indicating that CLA can be as beneficial in a functional food matrix as it is when taken in a supplement.1
After self-affirming Tonalin® CLA as GRAS in 2004 in consultation with a panel of independent experts, Cognis submitted this voluntary notification to the FDA in coordination with Lipid Nutrition, another branded CLA manufacturer. The FDA’s written response provides assurance to food manufacturers and consumers that the FDA has reviewed the submitted safety evidence and does not object to the overall GRAS conclusion for Tonalin® CLA in its intended use in the above food categories.
According to scientific evidence, Tonalin®, the #1 consumer brand of CLA worldwide, helps consumers reduce body fat up to 9 percent, prevent fat regain, and improve the ratio of lean body mass to body fat. Tonalin® works by decreasing the amount of fat stored after eating, increasing the rate of fat breakdown and metabolism, helping the body use its existing fat for energy, and decreasing the total number of fat cells. Tonalin®’s effectiveness has been confirmed by 17 clinical trials published in peer-reviewed journals.
“Tonalin® could help revolutionize the way people reduce body fat,” said David Eckert, Vice President, Cognis Nutrition & Health. “Our goal is to support our customers as they help consumers achieve their body composition goals with delicious, yet healthy foods and beverages. As the most recognized brand of CLA, Tonalin® is the ingredient of choice for functional food and beverages targeting consumers interested in safely and effectively improving their body composition by reducing body fat.”
Mr. Eckert pointed out that Cognis offers a unique service perfect for food companies launching new products with Tonalin®. Through its partnership with WILD Flavors, Inc., Cognis and WILD offer turn-key Tonalin® solutions to assist food manufacturers achieve stable, great-tasting products. “We help our customers avoid the often time-consuming and costly hurdles often associated with adding new functional ingredients.” More on this topic will be discussed in the August 14 webcast.
About Tonalin® CLA:
 Tonalin® is the original brand of CLA and is an exclusively licensed product of the Cognis Group. CLA is a polyunsaturated, conjugated fatty acid that is a natural part of the human diet, found primarily in meat and dairy products. Cognis produces Tonalin® CLA through a proprietary process that converts linoleic acid from safflowers into CLA, providing the highest quality of CLA available. Tonalin® contains the lowest amount of non-naturally occurring isomers, a patent-protected attribute that provides customers with the highest levels of active CLA isomers.
Tonalin® CLA is available in several product forms – oil, water-dispersible powder and emulsions – which offer food manufactures a broad range of options and easy processing for their new products. Tonalin® CLA is naturally sourced from safflowers, a sustainable and renewable raw material, and is not labeled as a trans fat.
Worldwide Recognition for the Tonalin® brand of CLA
The National Institutes of Health Office of Dietary Supplements in its Annual Bibliography of Significant Advances in Dietary Supplement Research (2004) included the landmark Tonalin® CLA study by Dr. Jean-Michel Gaullier as one of 25 “exemplary” papers. Cognis is the recipient of The 2007 Global Frost & Sullivan Award for Brand Development Strategy Leadership in the CLA market. “More studies on CLA and body composition have been published using Tonalin® than any other CLA brand,” noted Frost & Sullivan Research Analysts. Tonalin® CLA also has been recognized as “Health Product of the Year in several countries, including Finland and Spain.
For more information about Tonalin® CLA or to place an order, visit www.cognis.com and www.tonalin.com, call 800.673.3702, e-mail cognis.custserv@cognis.com, or fax 513.482.3576.
About Cognis:
 Cognis (www.cognis.com) is a worldwide supplier of innovative specialty chemicals and nutritional ingredients, with a particular focus on the areas of wellness and sustainability. The company employs about 7,600 people, and it operates production sites and service centers in 30 countries. Cognis has dedicated its activities to a high level of sustainability and delivers natural source raw materials and ingredients for food, nutrition and healthcare markets, and the cosmetics, detergents and cleaners industries. Another main focus is on products for a number of other industries, such as coatings and inks, lubricants, as well as agriculture and mining. Cognis is owned by private equity funds advised by Permira, GS Capital Partners, and SV Life Sciences. In 2007, Cognis recorded sales of about 3.52 billion euros and an Adjusted EBITDA (operating result) of 410 million euros.
About Dr. Elizabeth Sloan of Sloan Trends, Inc.
 Dr. A. Elizabeth Sloan is the President of Sloan Trends, Inc., an Escondido, California based consulting firm that offers trend-tracking and predictions, strategic counsel and business-building ideas for food, supplement and food service/restaurant marketers. She has written more than 150 articles, co-authored two college text books on nutrition and has appeared on numerous radio and television programs, including The Today Show, Good Morning America and CBS and NBC newscasts. Dr. Sloan holds a Ph.D. in Food Science and Nutrition with a minor in Mass Communications from the University of Minnesota and a Bachelors degree in Food Technology from Rutgers University.
1 - Laso, N., Bruque, E., Vidal, J., Ros, E., Arnaiz, JA., Carne, X., Vidal, S., Mas, S., Deulofeu, R.,
Lafuente, A.: Effect of milk supplementation with conjugated linoleic acid (isomers cis-9, trans-11 and trans-10, cis-12) on body composition and metabolic síndrome components. British Journal of Nutrition 2007; Jul 11: 1-8.
### |